NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

Diabetes - Tập 52 Số 5 - Trang 1210-1214 - 2003
Charles M. Alexander1, Pamela B. Landsman1, Steven M. Teutsch1, Steven E. Kahn2
1Outcomes Research & Management, U.S. Medical & Scientific Affairs, Merck & Co., Inc., West Point, Pennsylvania
2Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas

Tóm tắt

Although the individual components of the metabolic syndrome are clearly associated with increased risk for coronary heart disease (CHD), we wanted to quantify the increased prevalence of CHD among people with metabolic syndrome. The Third National Health and Nutrition Examination Survey (NHANES III) was used to categorize adults over 50 years of age by presence of metabolic syndrome (National Cholesterol Education Program [NCEP] definition) with or without diabetes. Demographic and risk factor information was determined for each group, as well as the proportion of each group meeting specific criteria for metabolic syndrome. The prevalence of CHD for each group was then determined. Metabolic syndrome is very common, with ∼44% of the U.S. population over 50 years of age meeting the NCEP criteria. In contrast, diabetes without metabolic syndrome is uncommon (13% of those with diabetes). Older Americans over 50 years of age without metabolic syndrome regardless of diabetes status had the lowest CHD prevalence (8.7% without diabetes, 7.5% with diabetes). Compared with those with metabolic syndrome, people with diabetes without metabolic syndrome did not have an increase in CHD prevalence. Those with metabolic syndrome without diabetes had higher CHD prevalence (13.9%), and those with both metabolic syndrome and diabetes had the highest prevalence of CHD (19.2%) compared with those with neither. Metabolic syndrome was a significant univariate predictor of prevalent CHD (OR 2.07, 95% CI 1.66–2.59). However, blood pressure, HDL cholesterol, and diabetes, but not presence of metabolic syndrome, were significant multivariate predictors of prevalent CHD. The prevalence of CHD markedly increased with the presence of metabolic syndrome. Among people with diabetes, the prevalence of metabolic syndrome was very high, and those with diabetes and metabolic syndrome had the highest prevalence of CHD. Among all individuals with diabetes, prevalence of CHD was increased compared with those with metabolic syndrome without diabetes. However, individuals with diabetes without metabolic syndrome had no greater prevalence of CHD compared with those with neither.

Từ khóa


Tài liệu tham khảo

Avogaro P, Crepaldi G, Enzi G, Tiengo A: Associazione di iperlipidemia, diabete mellito e obesità di medio grado. Acta Diabetol Lat 4: 36–41,1967

Haller H: Epidemiologie und assoziierte Risikofaktoren der Hyperlipoproteinamie [Epidemiology and associated risk factors of hyperlipoproteinemia]. Z Gesamte Inn Med 32: 124–128,1977

Singer P: Zur Diagnostik der primaren Hyperlipoproteinamien [Diagnosis of primary hyperlipoproteinemias]. Z Gesamte Inn Med 32: 129–133,1977

Ferrannini E, Haffner SM, Mitchell BD, Stern MP: Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34: 416–422,1991

Reaven GM: Role of insulin resistance in human disease. Diabetes 37: 1595–1607,1988

Reaven GM: Syndrome X. Blood Press Suppl 4: 13–16,1992

Meigs JB, D’Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE: Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 46: 1594–1600,1997

Gerstein HC: Is glucose a continuous risk factor for cardiovascular mortality?Diabetes Care 22: 659–660,1999

DECODE Study Group: Glucose tolerance and cardiovascular mortality. Arch Intern Med 161: 397–404,2001

DECODE Study Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354: 617–621,1999

Haffner SM: Impaired glucose tolerance: is it relevant for cardiovascular disease?Diabetologia 40 (Suppl. 2): S138–S140,1997

Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, Eschwege E: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policeman Study. Diabetes Care 21: 360–367,1998

Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE: Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study. Ann Intern Med 128: 524–533,1998

Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683–689,2001

Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 279: 1955–1961,1998

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486–2497,2001

Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287: 356–359,2002

National Center for Health Statistics: Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988–1994. Hyattsville, MD, National Center for Health Statistics,1994 (Vital and Health Statistics Series 1, no. 32)

Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey 1988–1994. Diabetes Care. 21: 518–524,1998

American Diabetes Association: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 209: 1183–1197,1997

Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 499–502,1972

McAuley K, Williams S, Mann J, Walker R, Lewis-Barned N, Temple L, Duncan A: Diagnosing insulin resistance in the general population. Diabetes Care 24: 460–464,2001

Haffner S, Miettinen H, Stern M: The homeostasis model in the San Antonio Heart Study. Diabetes Care 20: 1087–1092,1997

Rose GA, Blackburn H, Gillium RF, Prineas RJ: Cardiovascular Survey Methods. 2nd ed. Geneva, Switzerland, World Health Organization,1982

Statistical Analysis Systems (SAS) version 8e for PC. SAS Institute Inc., Cary, NC

Software for survey design analysis (SUDAAN) version 7.5.3. Research Triangle Institute, Research Triangle Park, NC,1998

Stout RW: Hyperinsulinemia and atherosclerosis. Diabetes 45 (Suppl. 3): S45–S46,1996

Festa A, D’Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42–47,2000

Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434–444,1993

Alexander CM, Landsman PB, Teutsch SM: Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol 86: 897–902,2000

Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP: The continuing epidemics of obesity and diabetes in the United States. JAMA 286: 1195–1200,2001

Thông tin
Thông tin xuất bản

Diabetes

Tập 52 Số 5

1210-1214

Thông tin tác giả